Dataciencia

Año	Factor de Impacto
2015	1.333
2016	1.667
2017	1.494
2018	1.483
2019	1.967
2020	1.967
2021	1.967

Año

Factor de Impacto

2015

1.333

2016

1.667

2017

1.494

2018

1.483

2019

1.967

2020

1.967

2021

1.967

Muestra la distribución de disciplinas para la revista.

Cuartiles desplegados de acuerdo a WoS, consultando el Journal Citation Report. Estos cuartiles pueden variar dependiendo de la disciplina consultada.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Nombre Revista	ISSN/ISBN	Indexacion	Citas
IMMUNOTHERAPY	1750-743X	Externa	1

Nombre Revista

ISSN/ISBN

Indexacion

Citas

IMMUNOTHERAPY

1750-743X

Externa

Título	Año	Citas
Primary Pfs And Safety Analyses Of A Randomized Phase Iii Study Of Carboplatin Plus Paclitaxel Plus / Bevacizumab, With Or Without Atezolizumab In 1 L Non Squamous Metastatic Nsclc (I Mpower150)	2018	1
Nivolumab (Nivo) Plus Low Dose Ipilimumab (Ipi) As First Line (1 L) Treatment (Tx) Of Advanced Nsclc: Overall Survival (Os) Analysis Of Checkmate 817	2020	0
Impower133: Updated Overall Survival (Os) Analysis Of First Line (1 L) Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide In Extensive Stage Sclc (Es Sclc)	2020	0
Checkmate 214 Post Hoc Analyses Of Nivolumab Plus Ipilimumab Or Sunitinib In Imdc Intermediate/Poor Risk Patients With Previously Untreated Advanced Renal Cell Carcinoma (Arcc) With Sarcomatoid Features (Srcc)	2020	0
Image Guided Radiation Therapy Based On Helical Tomotherapy In Prostate Cancer: Minimizing Toxicity	2014	0
Long Term Follow Up On Overall Survival And Independent Review Of Response In Check Mate 214: First Line Nivolumab Plus Ipilimumab (N Plus I) Versus Sunitinib (S) In Patients (Pts) With Advanced Renal Cell Carcinoma (A Rcc)	2020	0
Chronos 3: Randomized Phase Iii Study Of Copanlisib Plus Rituximab Vs Rituximab/Placebo In Relapsed Indolent Non Hodgkin Lymphoma (I Nhl)	2021	0
First Line (1 L) Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo In Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): Expanded Efficacy And Safety Data From Check Mate 649	2021	0
Lenvatinib Plus Pembrolizumab For Patients With Previously Treated Biliary Tract Cancers In The Multicohort Phase 2 Leap005 Study	2021	0
Nivolumab Plus Cabozantinib (N Plus C) Vs Sunitinib (S) For Advanced Renal Cell Carcinoma (A Rcc): Outcomes By Baseline Disease Characteristics In The Phase 3 Check Mate 9 Er Trial	2021	0
First Line (1 L) Nivolumab (Nivo) Plus Ipilimumab (Ipi)+2 Cycles Of Chemotherapy (Chemo) Vs Chemo Alone (4 Cycles) In Patients (Pts) With Metastatic Non Small Cell Lung Cancer (M Nsclc): 3 Year Update From Check Mate 9 La	2022	0
First Line Therapy With Nivolumab (Nivo) Plus Ipilimumab (Ipi)+2 Cycles Of Chemotherapy (Chemo) Vs Chemotherapy Alone (4 Cycles) In Patients (Pts) With Metastatic Non Small Cell Lung Cancer (M Nsclc): 3 Year Update Of Check Mate 9 La	2022	0
Nivolumab (Nivo) Plus Chemotherapy (Chemo) Vs Chemo As First Line (1 L) Treatment For Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma (Gc/Gejc/Eac): 3 Year Follow Up From Check Mate 649	2023	0
Pembrolizumab (Pembro) Plus Gemcitabine And Cisplatin (Gem/Cis) In Patients (Pts) With Advanced Biliary Tract Cancer (Btc): Results From The Randomized, Double Blind Phase 3 Keynote 966 Study	2023	0

Título

Año

Citas

Primary Pfs And Safety Analyses Of A Randomized Phase Iii Study Of Carboplatin Plus Paclitaxel Plus / Bevacizumab, With Or Without Atezolizumab In 1 L Non Squamous Metastatic Nsclc (I Mpower150)

2018

Nivolumab (Nivo) Plus Low Dose Ipilimumab (Ipi) As First Line (1 L) Treatment (Tx) Of Advanced Nsclc: Overall Survival (Os) Analysis Of Checkmate 817

2020

Impower133: Updated Overall Survival (Os) Analysis Of First Line (1 L) Atezolizumab (Atezo) Plus Carboplatin Plus Etoposide In Extensive Stage Sclc (Es Sclc)

2020

Checkmate 214 Post Hoc Analyses Of Nivolumab Plus Ipilimumab Or Sunitinib In Imdc Intermediate/Poor Risk Patients With Previously Untreated Advanced Renal Cell Carcinoma (Arcc) With Sarcomatoid Features (Srcc)

2020

Image Guided Radiation Therapy Based On Helical Tomotherapy In Prostate Cancer: Minimizing Toxicity